Jack Vander Aarde from Maxim Group issued a price target of $25.00 for MRAM on 2026-10-12 11:54:13.The adjusted price target was set to $25.00.At the time of the announcement, MRAM was trading at $16.45.The overall price target consensus is at $19.00 with high price of $19.00, low price of $19.00, and median price is at...
VCI Global Limited (VCIG) confirmed earnings release on October 12, 2026, Before the market for the...
Virtus Total Return Fund Inc. (ZTR) declaring a stock dividend of $0.055 per share on Ex-Date...
Virtus Global Multi-Sector Income Fund (VGI) declaring a stock dividend of $0.08 per share on Ex-Date...
Cohen & Steers Real Estate Opportunities & Income Fund (RLTY) declaring a stock dividend of $0.11...
Jack Vander Aarde from Maxim Group issued a price target of $25.00 for MRAM on 2026-10-12 11:54:13.The adjusted price target was set to $25.00.At the time of the announcement, MRAM...
Matthew Caufield from H.C. Wainwright issued a price target of $126.00 for KOD on 2026-10-12 10:50:00.The adjusted price target was set to $126.00.At the time of the announcement, KOD was...
William Plovanic from Canaccord Genuity issued a price target of $10.00 for BFLY on 2026-10-12 09:15:58.The adjusted price target was set to $10.00.At the time of the announcement, BFLY was...
Alice Nettleton from UBS issued a price target of $53.00 for NKTR on 2026-10-12 06:21:00.The adjusted price target was set to $53.00.At the time of the announcement, NKTR was trading...
from UBS issued a price target of $17.00 for STTK on 2026-10-11 23:37:15.The adjusted price target was set to $17.00.At the time of the announcement, STTK was trading at $5.97.The...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
